FLOW 试验:司美格鲁肽在不同 CKD 严重程度中的肾脏与生存结局
FLOW 试验事后分析按基线 eGFR 和 UACR 分层,评估司美格鲁肽 1 mg 每周一次对 2 型糖尿病合并 CKD 患者的肾脏复合结局和全因死亡影响。结果显示主要肾脏结局风险降低(HR 0.76,95%CI 0.66–0.88),全因死亡风险降低(HR 0.80,95%CI 0.67–0.95),且在各 eGFR/UACR 亚组中基本一致,支持在 FLOW 覆盖的 CKD 严重程度谱(包括晚期 CKD)中使用司美格鲁肽。
要点
- 司美格鲁肽降低主要肾脏复合结局风险(HR 0.76,95%CI 0.66–0.88)。
- 全因死亡风险降低(HR 0.80,95%CI 0.67–0.95)。
- 肾脏获益在各 eGFR 和 UACR 亚组中一致。
核心结论
- 司美格鲁肽在广泛基线 eGFR 和 UACR 类别中降低主要肾脏疾病事件和全因死亡风险,支持 2 型糖尿病合并 CKD(包括晚期 CKD)患者使用司美格鲁肽。
研究设计与样本
- FLOW 为双盲、随机、安慰剂对照试验,中位随访 3.4 年(四分位距 2.9–4.0 年)。
- 入组 2 型糖尿病伴 eGFR 50–75 ml/min/1.73 m² 且 UACR >300 至 <5000 mg/g,或 eGFR 25 至 <50 ml/min/1.73 m² 且 UACR >100 至 <5000 mg/g。
- 随机接受皮下司美格鲁肽 1 mg 每周一次或安慰剂。
- 按基线 eGFR(<30 至 ≥60 ml/min/1.73 m²)或 UACR(<100 至 ≥2000 mg/g)分层评估结局。
主要发现
- 基线平均 eGFR 为 47±15 ml/min/1.73 m²,UACR 中位数(第 5–95 百分位)为 568(51–3225)mg/g。
- 主要结局在司美格鲁肽组 vs 安慰剂组的发生率为 19%(331/1767)vs 23%(410/1766),HR 0.76(95%CI 0.66–0.88)。
- 全因死亡在司美格鲁肽组 vs 安慰剂组为 13%(227/1767)vs 16%(279/1766),HR 0.80(95%CI 0.67–0.95)。
- 主要结局的 HR 在各 eGFR 和 UACR 亚组中一致(交互 P 分别为 0.83 和 0.42)。
- 全因死亡的 HR 在各 eGFR 亚组中一致(交互 P=0.54),UACR ≥2000 mg/g 者 HR 最低(0.47,95%CI 0.31–0.70),交互 P=0.02。
临床怎么用
- 对于 2 型糖尿病合并 CKD(包括晚期 CKD)患者,可考虑使用司美格鲁肽 1 mg 每周一次以降低肾脏事件和死亡风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
KEY POINTS: Semaglutide reduced kidney outcome risk across broad CKD severity strata (eGFR; albuminuria). Reduced risk for all-cause death also carried through strata of CKD severity. In a population with type 2 diabetes, semaglutide improved kidney and survival outcomes irrespective of CKD severity, including advanced CKD. BACKGROUND: Semaglutide improved kidney and overall survival in participants with type 2 diabetes (T2D) and CKD in the Evaluate Renal Function with Semaglutide Once Weekly (FLOW) trial. The aim of the present analyses was to quantify these benefits across broad strata of CKD severity. METHODS: FLOW was a double-blind, randomized, placebo-controlled trial (median follow-up 3.4 [interquartile range, 2.9-4.0] years). Participants with T2D and eGFR 50-75 ml/min per 1.73 m 2 and urine albumin-to-creatinine ratio (UACR) >300 to <5000 mg/g, or eGFR 25 to <50 ml/min per 1.73 m 2 and UACR >100 to <5000 mg/g, were randomized to subcutaneous semaglutide 1 mg once-weekly or placebo. Subgroups were categorized by baseline eGFR (<30 to ≥60 ml/min per 1.73 m 2 ) or UACR (<100 to ≥2000 mg/g) to assess the primary outcome and individual components (≥50% eGFR decline, eGFR <15 ml/min per 1.73 m 2 , dialysis, kidney transplant, and death due to kidney or cardiovascular causes), all-cause death, eGFR, and UACR. RESULTS: At baseline, the mean±SD eGFR was 47±15 ml/min per 1.73 m 2 , and the median (5th-95th percentile) UACR was 568 (51-3225) mg/g. The primary outcome occurred in 19% (331 of 1767) versus 23% (410 of 1766) with semaglutide treatment versus placebo (hazard ratio [HR], 0.76; 95% confidence interval [CI], 0.66 to 0.88). Death occurred in 13% (227 of 1767) versus 16% (279 of 1766), respectively (HR, 0.80; 95% CI, 0.67 to 0.95). Across eGFR and UACR subgroups, HRs for the primary outcome remained consistent ( P for interaction 0.83 and 0.42, respectively). For death, HRs were consistent among eGFR subgroups ( P for interaction 0.54), but the HR was lowest (0.47; 95% CI, 0.31 to 0.70) for those with UACR ≥2000 mg/g ( P for interaction 0.02). Estimated treatment effects on eGFR and UACR were generally consistent among subgroups. CONCLUSIONS: Semaglutide reduced risks of major kidney disease events and all-cause death across wide-ranging categories of baseline eGFR and UACR, supporting semaglutide treatment in T2D throughout the spectrum of CKD severity represented in FLOW, including advanced CKD.Clinical Trial registry name and registration number: NCT03819153 .
引用
- Tuttle KR, Mann JFE, Mayrdorfer MM, et al. Kidney and Survival Outcomes with Semaglutide by CKD Severity in the FLOW Trial. Clin J Am Soc Nephrol. 2026. PMID: 41706532. doi:10.2215/CJN.0000000974
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。